Author

P. Galbo

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 2 Research Focus:cancer & tumor microenvironment· 2 Research Focus:differential expression· 2 Approach:experimental assay· 2 Organism:human· 2 Approach:statistical model· 2 Research Focus:cell type annotation· 1 Research Focus:cell-cell communication· 1

Frequent Co-Authors

D. Zheng· 2 shared A. A. Hamid· 1 shared A. D. Choudhury· 1 shared A. Mitrofanova· 1 shared A. S. Kibel· 1 shared A. Sowalsky· 1 shared A. Storey· 1 shared A. Tackett· 1 shared

Activity by Year

2019-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 24 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersImmunology

D. Zheng

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Fine-tuning spatial-temporal dynamics and surface receptor expression support plasma cell-intrinsic longevity

Z. Jing, P. Galbo, L. Ovando, M. Demouth, S. Welte, R. Park, K. Chandran, Y. Wu, T. MacCarthy, D. Zheng, D. Fooksman

This study identifies unique features of long-lived plasma cells (LLPCs), including reduced motility, clustering, and specific surface markers, and shows that CXCR4 is critical for their survival and antibody production.

bioRxiv · Feb 15, 2023Immunology

YY1 cistrome analysis uncovers an essential requirement of the YY1:BRD4-PFKP regulatory axis for promoting tumorigenesis of castration-resistant prostate cancer

L. Cai, C. Xu, Y.-H. Tsai, P. Galbo, W. Gong, A. Storey, Y. Xu, S. Byrum, Y. Whang, J. Parker, S. Mackintosh, R. Edmondson, A. Tackett, J. Huang, D. Zheng, , G. G. Wang

This study identifies a YY1:BRD4-PFKP regulatory axis critical for castration-resistant prostate cancer tumorigenesis through cistrome analysis and functional experiments.

bioRxiv · Sep 17, 2020 · PreprintCancer Biology

Targeting EZH2 Increases Therapeutic Efficacy of Check-Point Blockade in Models of Prostate Cancer

A. V. Sheahan, K. L. Morel, D. L. Burkhart, S. C. Baca, D. P. Labbe, K. Roehle, M. Heckler, C. Calagua, H. Ye, P. Galbo, S. Panja, A. Mitrofanova, A. A. Hamid, A. S. Kibel, A. D. Choudhury, , L. Ellis

This study shows that inhibiting EZH2 enhances the effectiveness of PD-1 checkpoint inhibitors in prostate cancer by increasing PD-L1 expression and immune cell infiltration.

bioRxiv · Aug 8, 2019 · PreprintCancer Biology